Recently, we reported treatment targeting CD226 can ameliorate experimental autoimmune encephalomyelitis (EAE) by promoting IL‐10 expression via regulation of CD4+ T cell differentiation (Zhang et al., 2016). Here, CD226 is linked to experimental autoimmune encephalomyelitis.